November 18, 2026 · BMC women's health · DOI: 10.1186/s12905-026-05114-6

Performance of a DNA methylation marker panel in cervical samples from women with abnormal cytology findings.

Listen to this summary

This study evaluated whether the GynTect DNA methylation panel (ASTN1, DLX1, ITGA4, RXFP3, SOX17, ZNF671) can serve as a more selective triage test than the p16/Ki-67 Dual Stain for women with abnormal cervical cytology. In 1,000 samples with cytology of LSIL or worse, GynTect was positive in 27.7% of cases versus 88.3% for p16/Ki-67, with positivity rising steadily with cytological and histological severity and all four carcinomas testing positive. The authors conclude that GynTect may offer higher selectivity for high-grade disease and reduce overtreatment, though prospective validation in HPV-screening triage populations is still needed.

Ilona Zeiser, Katja Schubert, Juliane Hippe, Alfred Hansel, Martina Schmitz, Magnus von Knebel Doeberitz, Andrè Ahr, Hans Ikenberg

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play